Please login to the form below
Biogen
This page shows the latest Biogen news and features for those working in and with pharma, biotech and healthcare.
Biogen reports new data backing long-term benefit of Spinraza
Biogen has revealed new data for its spinal muscular atrophy (SMA) treatment Spinraza, showing long-term benefit and new insights into the development of a higher dose of the treatment. ... Previously, Biogen reported safety data from part A of the
Latest news
-
Biogen to begin shipping newly approved Alzheimer’s treatment in two weeks
Biogen is planning to ship its newly approved Alzheimer’s treatment Aduhelm in approximately two weeks, chief executive officer (CEO) Michel Vounatsos said in an investor call this week. ... Biogen’s drug is the first treatment approved by the FDA
-
FDA approves Biogen’s aducanumab for Alzheimer’s disease in ‘landmark’ decision
FDA is requiring Biogen to conduct a new randomised, controlled clinical trial to verify the drug’s clinical benefit for Alzheimer’s patients. ... Biogen’s aducanumab has been approved by the US Food and Drug Administration (FDA) for the treatment
-
Biogen and Envisagenics to advance RNA splicing research for CNS diseases
Biogen and Envisagenics are collaborating to advance ribonucleic acid (RNA) splicing research within the central nervous system (CNS) diseases area. ... Envisagenics and Biogen recognise the power of RNA splicing to aid in the discovery of potential
-
Biogen and Capsigen to collaborate on gene therapies
Biogen will gain exclusive right for undisclosed number of CNS and neuromuscular disease targets. ... Capsigen. “Biogen is a leader in neuroscience, and we are excited for the opportunity to work with them to potentially bring new treatments to patients
-
Biogen to open compassionate use programme for ALS patients with ‘rapidly progressive disease’
This stage will come before the safety and efficacy of the drug are established, Biogen noted. ... The EAP for tofersen will start before Biogen submits applications for regulatory approval of the drug.
Biogen to begin shipping newly approved Alzheimer’s treatment in two weeks
FDA approves Biogen’s aducanumab for Alzheimer’s disease in ‘landmark’ decision
More from news
Approximately 141 fully matching, plus 316 partially matching documents found.
Latest Intelligence
-
After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream
Another example is Biogen’s $800m acquisition of Nightstar’s late-stage gene therapy assets for retinal disease – NSR-REP1 and NSR-RPGR.
-
Switzerland: a life sciences hub
The country is thus home to AbbVie, Allergan, Amgen, AstraZeneca, Bayer, Biogen, Boehringer Ingelheim, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Lundbeck, MSD (Merck Sharp &Dohme), Pfizer, Sanofi and Takeda among others.
-
Alzheimer’s: the search for a cure
The whiplash turnaround is the result of Biogen’s analysis of data from two phase 3 trials. ... Baird analyst Brian Skorney is among the people who have a dim view of Biogen’s prospects.
-
20 for 2020 – Five pharma leaders to watch in 2020
Analysts think the deal could catapult Galapagos into the top tier of biopharma companies, joining the likes of Regeneron, Biogen and Roche’s Genentech unit, providing its pipeline delivers as hoped
-
Great expectations: the urgent need for common purpose in Alzheimer’s disease
Biogen surprised the world last autumn by announcing a re-evaluation of its latest aducanumab trial and the company is now expected to apply for regulatory approval.
After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream
Switzerland: a life sciences hub
Alzheimer’s: the search for a cure
20 for 2020 – Five pharma leaders to watch in 2020
Great expectations: the urgent need for common purpose in Alzheimer’s disease
More from intelligence
Approximately 2 fully matching, plus 45 partially matching documents found.
Latest appointments
-
BMS appoints new commercial leader, Davies joins Eisai and more
operations. She joins Sobi from Biogen, where she served as vice president for global supply chain operations and strategic partnerships.
-
Biogen appoints executive VP, corporate development
Biogen has appointed Daniel Karp as its executive vice president, corporate development effective 11 June. ... He will also become a member of the executive committee and will report directly to chief executive officer Michel Vounatsos, who said: “We
-
Gamida Cell strengthens leadership team
Nee will lead market research, analytics, forecasting, commercial strategies and competitive intelligence at the company, activities he has practised during his time with Biogen, Amgen and Novartis.
-
Editas Medicine names James Mullen as chairman
Before joining Patheon, Mullen served as chief executive officer and president at Biogen and before this he held numerous roles at the biotech.
-
Acumen appoints new strategy director
Thomas Bols will focus on reinforcing Acumen’s healthcare practice
BMS appoints new commercial leader, Davies joins Eisai and more
Biogen appoints executive VP, corporate development
Gamida Cell strengthens leadership team
Editas Medicine names James Mullen as chairman
Acumen appoints new strategy director
More from appointments
Approximately 16 fully matching, plus 32 partially matching documents found.
Latest from PMHub
-
Mednet Group
Alzheimer’s Research UK. Alzheimer’s Society. Basic Needs. Biogen. Butterfly Scheme. Cardiomyopathy UK.
-
EPG Health
Strategic planning - to ensure ongoing engagement and success. Alexion, Almirall, Alnylam, AstraZeneca, Bial, Biogen, Bluebird Bio, Boehringer Ingelheim, BMS, CSL Behring, Ferring, Four Health, GSK, HRA Pharma, Janssen, Leo Pharma, Lilly,
-
Article: Market access in Brazil
In April 2019, Brazilian Health Minister Luiz Henrique Mandetta announced a pilot agreement for access to Biogen’s Spinal Muscular Atrophy (SMA) treatment Spinraza (nusinersen) through the Sistema Único de Saúde
-
IGNIFI
Allergan. Biogen. Boehringer Ingelheim. CO.DON. Danone Nutricia. Ferring Pharmaceuticals. Kyowa Kirin.
-
Wallace Health
Our expertise spans healthcare providers, pharmaceuticals and consumer health and we work for clients including HCA Hospitals, Alliance Medical, GSK and Biogen as well as high-performing start-ups such as
Mednet Group
EPG Health
IGNIFI
More from PMHub
Approximately 1 fully matching, plus 10 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Senior Account Manager
-
Salary TBC
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Group Account Director, Patient Engagement & Solutions, Lond...
-
Highly competitive salary
-
Planner
-
Salary TBC
- Client Services Director, Patient Engagement & Solutions, Lo...
-
Highly competitive salary
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
-
Publications Director
-
Competitive Salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- Novartis highlights potential of its radioligand therapy in prostate cancer at ASCO
- Eli Lilly demonstrates Verzenio win in high-risk breast cancer subset at ASCO
- Merck & Co spinoff Organon launches with the aim of 'improving health outcomes for women'
- Positive results for AZ, Merck & Co’s Lynparza in early breast cancer presented at ASCO
- CanSinoBIO considers booster jab for COVID-19 vaccine
- BeiGene’s reveals positive data for Brukinsa in head-to-head Imbruvica trial
- BMS, Acceleron’s Reblozyl shows new improvements for beta thalassemia patients
- Biogen reports new data backing long-term benefit of Spinraza
- G7 expected to donate one billion COVID-19 vaccine doses
- Anna Korving joins Resonant Group as non-executive director
- Resonant Group appoints Stephen Marchant as chief development officer
- Novo Nordisk says Victoza outperforms SGLT2 inhibitors
- Israel finds a ‘probable link’ between Pfizer vaccine and myocarditis cases
- Merck signs $1.2bn supply deal with US government for Molnupiravir
- BMS, Acceleron’s Reblozyl shows new improvements for beta thalassemia patients
- G7 expected to donate one billion COVID-19 vaccine doses
- Keytruda is first FDA-approved drug for molecular indication
PMHub
TRIDUCIVE
Triducive are a strategic healthcare consultancy who produce communications that have practical, dynamic application that encourage behaviour change because of the...
Latest intelligence
- Article:
- The disparity of patient experiences with Crohn’s Disease in Europe and Japan...
- The pursuit of patient diversity in clinical trials
- When all-inclusive isn’t an option, it’s an obligation...
- Overcoming the digital patient recruitment challenges of connecting with patients
- How many irrelevant experiences, ads, emails, direct messages have you rejected this week?...
